XML 32 R19.htm IDEA: XBRL DOCUMENT
v3.21.2

Stock Option and Grant Plan | 6 Months Ended
--- | ---
Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock Option and Grant Plan | 12. Stock option and grant plan Stock option and grant plan The Beam Therapeutics Inc. 2017 Stock Option and Grant Plan adopted by the Company’s board of directors in June 2017 and amended in each of February 2019 and May 2019 provided for the grant of qualified incentive stock options and nonqualified stock options, restricted stock awards, restricted stock units, or other awards to the Company’s employees, officers, directors, advisors, and outside consultants for the issuance or purchase of shares of the Company’s common stock. In October 2019, the Company’s board of directors adopted the Beam Therapeutics Inc. 2019 Equity Incentive Plan, or the 2019 Plan, and, subsequent to the IPO, all equity-based awards are granted under the 2019 Plan. The 2019 Plan provides for the grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company’s employees, officers, directors, advisors, and outside consultants. As of June 30, 2021, the Company had 9,188,648 shares reserved including 2,555,874 shares available for future issuance pursuant to the 2019 Plan. Stock-based compensation expense recorded as research and development and general and administrative expenses in the condensed consolidated statements of operations and other comprehensive loss is as follows (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Research and development |  | $ | 6,340 |  |  | $ | 1,805 |  |  | $ | 9,495 |  |  | $ | 3,578 |
General and administrative |  |  | 4,112 |  |  |  | 964 |  |  |  | 5,605 |  |  |  | 1,983 |
Total stock-based compensation expense |  | $ | 10,452 |  |  | $ | 2,769 |  |  | $ | 15,100 |  |  | $ | 5,561 |
Stock options The following table provides a summary of option activity under the Company’s equity award plans:
|  | Number of options |  |  | Weighted average exercise price |
Outstanding at December 31, 2020 |  |  | 5,336,441 |  |  | $ | 9.70 |
Granted |  |  | 1,236,543 |  |  |  | 86.38 |
Exercised |  |  | (605,509 | ) |  |  | 9.65 |
Forfeitures |  |  | (32,731 | ) |  |  | 28.84 |
Outstanding at June 30, 2021 |  |  | 5,934,744 |  |  |  | 25.58 |
Exercisable as of June 30, 2021 |  |  | 1,733,868 |  |  | $ | 7.48 |
The weighted-average grant date fair value per share of options granted in the six months ended June 30, 2021 was $57.33. As of June 30, 2021, there was $90.3 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.5 years. Restricted stock The Company issues shares of restricted common stock, including both restricted stock units and restricted stock awards. Restricted common stock issued generally vests over a period of two to four years. The following table summarizes the Company’s restricted stock activity:
|  | Shares |  |  | Weighted- average grant date fair value |
Unvested as of December 31, 2020 |  |  | 1,275,338 |  |  | $ | 10.95 |
Issued |  |  | 619,030 |  |  |  | 88.49 |
Vested |  |  | (599,207 | ) |  |  | 4.44 |
Cancelled |  |  | (4,500 | ) |  |  | 80.04 |
Unvested as of June 30, 2021 |  |  | 1,290,661 |  |  | $ | 51.04 |
At June 30, 2021, there was approximately $62.4 million of unrecognized stock-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted-average period of approximately 2.2 years. In February 2020, the Company’s board of directors adopted the Beam Therapeutics Inc. 2019 Employee Stock Purchase Plan, or ESPP, which was approved by the Company’s stockholders. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $25,000 and at a purchase price of 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The first offering period is expected to commence on October 1, 2021. As of June 30, 2021, the Company had 1,049,460 shares available for issuance under the ESPP.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration